Table 4:

Nucleoside Transporter Alterations in Cancer

Nucleoside transporter	Cancer subtype	Reference
ENT1	Biliary tract	(J. Kim, et al., 2018)
	Cholangiocarcinoma	(Borbath, et al., 2012; Kawamoto, et al., 2018)
	Pancreatic	(Farrell, et al., 2009; Hagmann, Jesnowski, & Lohr, 2010; Hu, et al., 2017; M. Liu, et al., 2020; Weadick, et al., 2021)
	Leukemia	(Abraham, et al., 2015; Homminga, et al., 2011; M. Huang, et al., 2004; J. H. Kim, et al., 2016; Macanas-Pirard, et al., 2012; Molina-Arcas, et al., 2003; Takagaki, et al., 2004; Zimmerman, et al., 2009)
	Breast	(Kenny, et al., 2009)
	Ovarian	(Bock, et al., 2012)
	Gallbladder adenocarcinoma	(Espinoza, et al., 2016)
	Colorectal	(Suenaga, et al., 2017)
	Glioblastoma	(Alarcon, et al., 2020)
ENT2	Ovarian	(Bock, et al., 2012)
	Pancreatic	(Nishio, et al., 2011)
	Leukemia	(Fotoohi, et al., 2006; Homminga, et al., 2011; M. Huang, et al., 2004; Molina-Arcas, et al., 2003)
ENT3	histiocytic sarcoma	(Hsu, et al., 2012)
CNT1	Lung	(P. J. Muller, et al., 2009)
	Pancreatic	(Bhutia, et al., 2011; Garcia-Manteiga, et al., 2003; Hesler, et al., 2016)
	hepatocellular carcinoma	(Zollner, et al., 2005)
	Breast	(Gloeckner-Hofmann, et al., 2006)
CNT3	Ovarian	(Bock, et al., 2012)
	Leukemia	(Fotoohi, et al., 2006)
	Pancreatic	(Hesler, et al., 2016)